On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of initiatives from various companies involved in innovating these technologies (read about those HERE). Those companies have contributed to […]
Sequel Med Tech
The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]
Sequel Med Tech’s unique twiist automated insulin delivery system brings something new to the space
Sequel Med Tech made significant waves when it announced the receipt of FDA clearance for an automated insulin delivery system in March. The company, founded just last year, brings significant expertise in a number of channels to the table, despite its short history. CEO Dr. Alan Lotvin co-founded Sequel, bringing decades of experience as an […]
Study backs Sequel Med Tech’s automated insulin pump that provides faster occlusion detection
A study looking at automated insulin delivery technology from Sequel Med Tech highlighted the ability to address delayed occlusion detection. According to Sequel, an insulin pump’s failure to deliver insulin in the right amount at the right time is a preventable cause of hospitalization. The company says advances in insulin delivery technology so far fail […]
FDA clears automated insulin delivery system from Sequel Med Tech
Sequel Med Tech announced today that its partner, DEKA R&D, won FDA 510(k) clearance for its automated insulin delivery (AID) system. The twist system, powered by Tidepool, directly measures the volume and flow of insulin delivered with every microdose. It offers the capability and flexibility to address each patient’s individual dosing needs. Sequel will market […]
